Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: Newsfilter
- Employee Incentive Program: On December 15, 2025, Castle Biosciences granted 139,494 restricted stock units (RSUs) to 83 employees, aimed at attracting talent and enhancing employee loyalty, which is expected to improve overall company performance.
- Grant Details: The RSUs were awarded under the company's 2022 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal installments annually, ensuring continued employee service.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to attracting and retaining key talent while enhancing investor confidence through compliance and transparency.
- Company Vision: Castle Biosciences focuses on improving health through innovative testing, particularly in dermatologic and gastroenterological diseases, and the RSU grants will further drive the company's strategic goals in personalized healthcare solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CSTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CSTL
Wall Street analysts forecast CSTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 47.20 USD with a low forecast of 41.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.160
Low
41.00
Averages
47.20
High
52.00
Current: 39.160
Low
41.00
Averages
47.20
High
52.00
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Castle Biosciences Expects 2025 Revenue to Exceed $340 Million
- Significant Revenue Growth: Castle Biosciences anticipates total revenue for 2025 to exceed $340 million, surpassing the previously guided range of $327-335 million, reflecting strong performance in its innovative test portfolio and bolstering confidence in future growth.
- Surge in Core Test Reports: Total test reports for core revenue drivers increased by 37% in 2025 compared to 2024, with DecisionDx-Melanoma reports reaching 39,083 and TissueCypher reports at 39,014, indicating a robust recovery in market demand.
- Successful New Test Launch: The limited access launch of AdvanceAD-Tx in November 2025 saw over 50% of 150 clinician offices placing orders within the first five weeks, demonstrating rapid market acceptance and further expanding the company's total addressable market.
- Strong Financial Position: Year-end 2025 cash and cash equivalents are expected to be approximately $300 million, alongside $184 million in marketable investment securities, showcasing a solid financial foundation that provides ample funding for future expansion and innovation.
Continue Reading
AstraZeneca Secures FDA Approval for Enhertu in First-Line Breast Cancer, Triggers $150M Milestone Payment
- FDA Approval: AstraZeneca and its partner Daiichi Sankyo's antibody-drug conjugate Enhertu has received FDA approval for first-line treatment of unresectable or metastatic HER2-positive breast cancer, marking a significant milestone in the U.S. market.
- Clinical Trial Results: The DESTINY-Breast09 study demonstrated that the Enhertu-Perjeta combination achieved a median progression-free survival of 40.7 months, a 51.5% improvement over the 26.9 months seen with the standard taxane chemotherapy, highlighting its superior efficacy.
- Financial Impact: This approval triggers a $150 million milestone payment from AstraZeneca to Daiichi Sankyo, further solidifying their global partnership and providing a new revenue growth avenue for AstraZeneca.
- Market Performance: Over the past year, AstraZeneca's stock has surged by 36.3%, significantly outperforming the industry average growth of 12.1%, reflecting strong market confidence in its newly approved drug and future growth potential.
Continue Reading